## Vemircopan

R

MedChemExpress

| Cat. No.:          | HY-139588  |        |
|--------------------|--|--------|
| CAS No.:           | 2086178-00-7   | 1      |
| Molecular Formula: | C <sub>29</sub> H <sub>28</sub> BrN <sub>7</sub> O <sub>3</sub>  | H N CO |
| Molecular Weight:  | 602.48   |        |
| Target:            | Complement System  |        |
| Pathway:           | Immunology/Inflammation  | N Y Y  |
| Storage:           | 4°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | N U    |

## SOLVENT & SOLUBILITY

| In Vitro | DMSO : 50 mg/mL (82.99 mM; Need ultrasonic)   |  |                    |           |            |  |
|----------|---|--|--------------------|-----------|------------|--|
|          | Preparing<br>Stock Solutions  | Mass<br>Solvent<br>Concentration       | 1 mg               | 5 mg      | 10 mg      |  |
|          |   | 1 mM                                   | 1.6598 mL          | 8.2990 mL | 16.5981 mL |  |
|          |   | 5 mM                                   | 0.3320 mL          | 1.6598 mL | 3.3196 mL  |  |
|          |   | 10 mM                                  | 0.1660 mL          | 0.8299 mL | 1.6598 mL  |  |
|          | Please refer to the so  | lubility information to select the app | propriate solvent. |           |            |  |
| In Vivo  | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.66 mM); Clear solution |  |                    |           |            |  |
|          | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)<br>Solubility: ≥1 mg/mL (1.66 mM); Clear solution          |  |                    |           |            |  |
|          | <ol> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil<br/>Solubility: ≥ 1 mg/mL (1.66 mM); Clear solution</li> </ol> |  |                    |           |            |  |

| BIOLOGICAL ACTIVITY |  |  |  |
|---------------------|--|--|--|
| Description         | Vemircopan (ALXN2050) is an orally active complement factor D inhibitor <sup>[1]</sup> . |  |  |
|                     |  |  |  |

## REFERENCES

[1]. Claire L Harris, et al. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol. 2018 Oct;102:89-119.

**Product** Data Sheet

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA